Micrima Signs Distribution Agreement with Hologic for its Novel Breast Imaging System MARIA®

COVID-19 to Substantially Increase the Demand for 3D Printing Medical Devices Market from Key End-use Industry Sectors Unveils Fact.MR

The global 3D printing medical devices market is expected to exceed US$ 1,700 Mn in revenues by 2022-end, according to a recent research by Fact.MR.

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash.

Global Surgical Lasers Market to Reach $10.1 Billion by 2027

1 Billion by 2027, growing at a CAGR of 9.7% over the analysis period 2020-2027. Solid-State Laser Systems, one of the segments analyzed in the report, is projected to record a 9.2% CAGR and reach US$3.9 Billion by the end of the analysis period.

Micrima Ltd (the “Company”), the breast imaging company, is pleased to announce that it has signed a distribution agreement with Hologic Inc., a global leader in women’s health, for the Company’s new radio-wave breast imaging system, MARIA®. Under the terms of the agreement, Hologic will act as the sales and distribution partner for Micrima in Germany, Austria and Switzerland (DACH).

The first installations of MARIA®, which received CE mark approval in 2015, are expected to take place in Germany in the coming months.

Micrima has been working to develop a breast imaging system that can be used frequently from a young age to reduce the number of deaths from breast cancer. MARIA® uses harmless radio-waves, does not require breast compression and is cost effective to use. Trials to date have proven that, as an adjunct to X-ray mammography, it is effective at locating cancers, particularly in the dense tissue associated with younger women. The Company plans to introduce tissue differentiation within the MARIA® scan as it rolls out higher levels of functionality over time.

Roy Johnson, Micrima’s Executive Chairman, said: “This is an exciting step for Micrima as we transition from the product development phase into the market. We are pleased to be working with one of the best recognised global companies in breast imaging, and look forward to launching MARIA® into further new territories.”

Heinz Gerhards, Managing Director of Hologic Medicor DACH, said: “We are excited to be working alongside Micrima in the introduction of this new technology to the wider market.”

Prof Iain Lyburn, Consultant Radiologist, Cheltenham General Hospital, said: “We have been involved in the evaluation of the MARIA® system for some time now and whilst it is currently offered as an adjunct to other imaging modalities, particularly where dense tissue is involved, the technique promises the exciting future ability to distinguish between tissue types. Any imaging modality that can readily give this sort of functional information has the potential to influence many points in the diagnostic and treatment pathways – there could be less need for biopsies and possibly a reduction in over treatment.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles